GlassScriptPhysician profile
Megha D Patel
NPI 1568951952
$1,486.55
in general payments reported to CMS, 2019-2025
16 companies · $748 in 2025
The $748 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $288 · 2024: $451 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.55 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $361.54 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $328.06 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $197.05 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $176.38 | 2023-2025 | |
| Dexcom, INC. | $85.69 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $61.98 | 2023-2025 | |
| Exact Sciences Corporation | $50.09 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $36.70 | 2023-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $34.20 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.70 | 2024-2025 | Xifaxan |
| Dynavax Technologies Corporation | $26.35 | 2024 | Heplisav-B |
| Abbott Laboratories | $24.33 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $21.29 | 2025 | Korlym |
| Actelion Pharmaceuticals US, INC. | $18.90 | 2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2025 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $14.75 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.